Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.
human pegivirus
lymphoma
meta-analysis
risk
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
22 08 2020
22 08 2020
Historique:
received:
22
03
2019
accepted:
20
09
2019
pubmed:
2
11
2019
medline:
28
4
2021
entrez:
1
11
2019
Statut:
ppublish
Résumé
Human pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas. We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype. The overall OR for lymphoma was 2.85 (95% CI, 1.98-4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98-16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76-2.85]), Northern Europe (2.90 [.45-18.7), and the Middle East (2.51 [.87-7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63-6.62]), follicular (3.01 [1.95-4.63]), marginal zone (1.90 [1.13-3.18]), and T-cell (2.11 [1.17-3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48-25.9]) and chronic lymphocytic leukemia (1.45 [.45-4.66]) were increased but did not achieve statistical significance. This meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Sections du résumé
BACKGROUND
Human pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas.
METHODS
We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype.
RESULTS
The overall OR for lymphoma was 2.85 (95% CI, 1.98-4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98-16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76-2.85]), Northern Europe (2.90 [.45-18.7), and the Middle East (2.51 [.87-7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63-6.62]), follicular (3.01 [1.95-4.63]), marginal zone (1.90 [1.13-3.18]), and T-cell (2.11 [1.17-3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48-25.9]) and chronic lymphocytic leukemia (1.45 [.45-4.66]) were increased but did not achieve statistical significance.
CONCLUSIONS
This meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Identifiants
pubmed: 31671178
pii: 5610711
doi: 10.1093/cid/ciz940
pmc: PMC7442854
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221-1228Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195568
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
PLoS One. 2017 Sep 14;12(9):e0184494
pubmed: 28910347
Cancer Res. 2014 Oct 1;74(19):5553-60
pubmed: 25115299
J Med Virol. 2000 May;61(1):52-8
pubmed: 10745232
Clin Infect Dis. 2018 Jan 6;66(1):29-35
pubmed: 29020289
J Clin Pathol. 1998 Sep;51(9):676-8
pubmed: 9930072
Br J Haematol. 2018 Sep;182(5):644-653
pubmed: 29808922
Science. 1996 Jan 26;271(5248):505-8
pubmed: 8560265
Infect Genet Evol. 2013 Oct;19:195-9
pubmed: 23871772
PLoS One. 2012;7(11):e50563
pubmed: 23209780
J Infect Dis. 2015 May 15;211(10):1585-96
pubmed: 25425697
Trop Biomed. 2011 Dec;28(3):589-98
pubmed: 22433888
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Hum Immunol. 2013 Dec;74(12):1559-62
pubmed: 23993984
Haematologica. 1998 Oct;83(10):957-8
pubmed: 9830812
Hepatology. 1998 Aug;28(2):379-84
pubmed: 9696000
Sci Transl Med. 2015 Sep 16;7(305):305ra144
pubmed: 26378244
J Infect Dis. 1997 Sep;176(3):586-92
pubmed: 9291303
Lancet. 2004 Jun 19;363(9426):2040-6
pubmed: 15207954
Br J Haematol. 1998 Dec;103(4):1206-7
pubmed: 9886343
JAMA. 2007 May 9;297(18):2010-7
pubmed: 17488966
Haematologica. 2002 Jul;87(7):714-8; discussion 718
pubmed: 12091122
J Gen Virol. 2017 Jan;98(1):2-3
pubmed: 28218572
J Viral Hepat. 2009 Nov;16(11):757-68
pubmed: 19758271
Vox Sang. 1998;74(3):161-7
pubmed: 9595643
Clin Lab Haematol. 2002 Apr;24(2):107-10
pubmed: 11985556
J Virol. 1998 Apr;72(4):3072-5
pubmed: 9525631
Hepatology. 1997 May;25(5):1285-6
pubmed: 9141455
Hepatology. 1999 Jan;29(1):245-9
pubmed: 9862873
Acta Haematol. 2004;112(4):189-93
pubmed: 15564729
J Infect Dis. 2006 Feb 1;193(3):451-4
pubmed: 16388494
J Med Virol. 1999 Jun;58(2):160-4
pubmed: 10335864
J Immunol. 2012 Sep 1;189(5):2211-6
pubmed: 22844114
J Virol. 2000 Oct;74(19):9125-33
pubmed: 10982359
Transfusion. 1997 Jun;37(6):569-72
pubmed: 9191815
PLoS Pathog. 2017 Feb 24;13(2):e1006232
pubmed: 28235043
J Gen Virol. 2014 Jun;95(Pt 6):1307-1319
pubmed: 24668525
J Immunol. 2013 Jun 15;190(12):6351-9
pubmed: 23686495
Int J Cancer. 2010 Jun 15;126(12):2885-92
pubmed: 19904755
J Gen Virol. 2011 Feb;92(Pt 2):233-46
pubmed: 21084497
Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8
pubmed: 18387498
J Clin Microbiol. 2006 Sep;44(9):3105-13
pubmed: 16954234
AIDS. 2008 Nov 12;22(17):2398-400
pubmed: 18981782
PLoS Pathog. 2015 Dec 11;11(12):e1005325
pubmed: 26658760
Int J Cancer. 2004 Aug 10;111(1):76-80
pubmed: 15185346
Hepatology. 1999 Apr;29(4):1259-61
pubmed: 10094973
Cancer Sci. 2004 Sep;95(9):745-52
pubmed: 15471561
Int J Cancer. 2011 Jun 15;128(12):3013; author reply 3012
pubmed: 20726003
N Engl J Med. 2017 Sep 28;377(13):1261-1272
pubmed: 28953438
Virology. 2003 Nov 25;316(2):191-201
pubmed: 14644602
J Med Virol. 2008 Nov;80(11):1933-40
pubmed: 18814245
Hepatology. 1997 Dec;26(6):1626-33
pubmed: 9398008
Arch Virol. 1997;142(3):545-55
pubmed: 9349300
Arch Virol. 2013 Sep;158(9):2023-30
pubmed: 23580178
Nat Med. 1995 Jun;1(6):564-9
pubmed: 7585124
AIDS. 2013 Jul 17;27(11):1829-32
pubmed: 23807277
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120